Phaseline

Targets › CNGA1

CNGA1 (Cyclic nucleotide-gated channel alpha-1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology.

Pore-forming subunit of the rod cyclic nucleotide-gated channel. Mediates rod photoresponses at dim light converting transient changes in intracellular cGMP levels into electrical signals. (UniProt, P29973)

Open in Phaseline: the race on CNGA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
VeonGen TherapeuticsVG901
AAV2-mediated gene therapy delivering functional CNGA1 gene
CNGA1Phase 1Retinitis Pigmentosa–

Conditions

Retinitis Pigmentosa (1)

Modalities

other (1)

Companies

VeonGen Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.